Evaluation of the response to early Ozurdex® therapy in patients with diabetic cystoid macular edema, refractory to laser or anti-VEGF therapy: Importance of risk factors

Poster Details

First Author: A.Sanchez Ramon SPAIN

Co Author(s):    M. Lopez Galvez   E. Ortega Alonso   M. Sanchez Santos   P. Ponton Mendez   R. Portilla Blanco   L. Fernandez Cherkasova              

Abstract Details


To evaluate the influence of risk factors in patients with diabetic macular edema (DME) treated with Ozurdex®, and to identify the duration of treatment effect and the safety of this drug.


University Hospital of Burgos, Burgos, Spain.


A retrospective, descriptive and observational study was conducted on patients with refractory DME treated with Ozurdex® in the University Hospital of Burgos, Spain, between 2012 and 2015, with a minimum follow up period of six months.


A total of 21 patients were included in this study, with a mean age of 69 years old. Almost all (95%) patients had type 2 diabetes mellitus, and 81% were treated with insulin. The mean time of evolution of diabetes mellitus (DM) in this series was 16 years (± 12). The mean HbA1c was 7.22 ± 1.06. The mean initial best corrected visual acuity (BCVA) was 0.72 (LogMAR ±0.33) and improved to 0.58 (LogMAR ±0.31) after 6 months of follow up. The initial central macular thickness (CMT) was 506μ ±99, and a reduction to 384μ ±128 was observed after 6 months of follow up. Taking into account the overall metabolic control of the patient, a statistically significant difference was found in the improvement in visual acuity (VA) after 3 months of follow up in patients with good metabolic control. The VA improvement and the CMT reduction in patients with less chronic DME was superior to that of patients with more chronic edema. Four patients experienced an intraocular pressure (IOP) elevation (27.5 mmHg ±4) after Ozurdex® treatment, which was controlled with topical medication. No other side effects related to Ozurdex® were registered.


Ozurdex® is an effective and safe treatment in the treatment of cystoid DME in patients that did not respond or poorly responded to other therapies. The overall metabolic control of the patient following the criteria of the American Diabetes Association (ADA) is related to the success of the treatment with Ozurdex®.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy